

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: FIRST, ERIC R.

Serial No.: 10/731,973

Filed: December 9, 2003

For: BOTULINUM TOXIN THERAPY
FOR SKIN DISORDERS

Examiner: TONGUE, LAKIA J

Group Art Unit: 1645

Confirmation No. 6433

Irvine, California

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant provides with regard to the above-identified patent application entitled BOTULINUM TOXIN THERAPY FOR SKIN DISORDERS, one copy of documents of which he is aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. These documents were disclosed in an International Search Report in the foreign counterpart of the above-identified application, and were received less than three (3) months ago. Please do not

hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Date: October 16, 2007

Respectfully submitted,
/STEPHEN DONOVAN/

Stephen Donovan
Registration Number 33,433

Please direct all inquiries and correspondence to:

Stephen Donovan
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4026
Fax: (714) 246-4249